Daniel Tasse
Daniel Tasse's purchase track record
Daniel Tasse has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/8/2024 | DBVT | $14K | -41.1% | -53.4% | +5.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
DBVT ADRs See Minor Gains as European ADRs Rise. The group of European stocks traded as ADRs in the U.S. edged up on Tuesday and opened higher on Monday. DBVT, an ADR of DBV Technologies, was part of that group and saw a modest lift in its price. The move reflects broader market sentiment for European ADRs rather than a company‑specific event.
Transaction History
| RGNX | ▲ Buy | Grant | 9,807 | $0 | 5/29/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 7,768 | $0 | 5/30/2025 | View on chart |
| RGNX | ▲ Buy | Grant | 4,790 | $0 | 5/31/2024 | View on chart |
| DBVT | ▲ Buy | Open Market | 17,094 | $14K | 3/8/2024 | View on chart |
| RGNX | ▲ Buy | Grant | 3,486 | $0 | 6/2/2023 | View on chart |
| RGNX | ▲ Buy | Grant | 3,010 | $0 | 6/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
RGNX Reports Positive 3-Year Data and Settles Patent Litigation
RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.
RGNX Reports Positive 3-Year Data and Settles Patent Litigation. RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.